These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11692469)

  • 1. Fabry disease: clinical features and recent advances in enzyme replacement therapy.
    Desnick RJ; Wasserstein MP
    Adv Nephrol Necker Hosp; 2001; 31():317-39. PubMed ID: 11692469
    [No Abstract]   [Full Text] [Related]  

  • 2. Amelioration of white-matter lesions in a patient with Fabry disease.
    Yamadera M; Yokoe M; Beck G; Mihara M; Oe H; Yamamoto Y; Sakoda S
    J Neurol Sci; 2009 Apr; 279(1-2):118-20. PubMed ID: 19185318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options.
    Möhrenschlager M; Pontz BF; Lanzl I; Podskarbi T; Henkel V; Ring J
    J Dtsch Dermatol Ges; 2007 Jul; 5(7):594-7. PubMed ID: 17610610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A.
    Machann W; Breunig F; Weidemann F; Sandstede J; Hahn D; Köstler H; Neubauer S; Wanner C; Beer M
    Eur J Heart Fail; 2011 Mar; 13(3):278-83. PubMed ID: 21149315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiokeratomas, Fabry disease and enzyme replacement therapy: still a challenge.
    Möhrenschlager M; Henkel V; Ring J
    Br J Dermatol; 2005 Jan; 152(1):177-8; author reply 178-9. PubMed ID: 15656825
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease with aortic regurgitation.
    Choi S; Seo H; Park M; Kim J; Hwang S; Kwon K; Her K; Won Y
    Ann Thorac Surg; 2009 Feb; 87(2):625-8. PubMed ID: 19161799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
    Lui CY; Ju H
    Am J Cardiol; 2006 Dec; 98(11):1557-8. PubMed ID: 17126672
    [No Abstract]   [Full Text] [Related]  

  • 10. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
    Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
    Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fabry's disease. An orphan disease that has found a solution: enzymatic replacement with alpha-galactosidase].
    Selgas R; García de Lorenzo A; Valdés F; Beck M
    Nefrologia; 2001; 21(5):443-7. PubMed ID: 11795012
    [No Abstract]   [Full Text] [Related]  

  • 13. Promoter dependence of plasmid-pluronics targeted alpha galactosidase A expression in skeletal muscle of Fabry mice.
    Lavigne MD; Pohlschmidt M; Novo JF; Higgins B; Alakhov V; Lochmuller H; Sakuraba H; Goldspink G; MacDermot K; Górecki DC
    Mol Ther; 2005 Nov; 12(5):985-90. PubMed ID: 15975851
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fabry disease in Italy: first epidemiologic and collaborative study].
    Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
    Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for Fabry's disease.
    Gahl WA
    N Engl J Med; 2001 Jul; 345(1):55-7. PubMed ID: 11439950
    [No Abstract]   [Full Text] [Related]  

  • 16. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
    Yam GH; Roth J; Zuber C
    Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry nephropathy and the case for adjunctive renal therapy.
    Wanner C; Breunig F
    J Am Soc Nephrol; 2007 Sep; 18(9):2426-8. PubMed ID: 17699807
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful long-term enzyme replacement therapy in a young adult with Fabry disease.
    Kampmann C; Kalkum G; Beck M; Whybra C
    Clin Genet; 2013 Apr; 83(4):395-6. PubMed ID: 22881192
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Anderson-Fabry disease.
    Linhart A
    Heart; 2008 Feb; 94(2):138-9. PubMed ID: 18195119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.